galangin
| Name | Norizalpinin | ||
| PubChem CID | 5281616 | ||
| Molecular Weight | 270.24g/mol | ||
| Synonyms |
galangin |
||
| Formula | C₁₅H₁₀O₅ | ||
| SMILES | C1=CC=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O | ||
| InChI | 1S/C15H10O5/c16-9-6-10(17)12-11(7-9)20-15(14(19)13(12)18)8-4-2-1-3-5-8/h1-7,16-17,19H | ||
| InChIKey | VCCRNZQBSJXYJD-UHFFFAOYSA-N | ||
| CAS Number | 548-83-4 | ||
| ChEMBL ID | CHEMBL309490 | ||
| ChEBI ID | CHEBI:5262 | ||
| KEGG ID | C10044 | ||
| Toxicity | Organism | Test Type | Route(Dose) |
| rat | LD50 | intraperitoneal(165 mg/kg) | |
| mouse | LD50 | intraperitoneal(254 mg/kg) | |
| rat | LD50 | oral(322 mg/kg) | |
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | GaoLiangJiang | ||
| Use Part | Rhizome | ||
| Habitat | HaiNan, GuangXi, YunNan, TaiWan, GuangDong | ||
| Flavor | Pungent | ||
| Meridian Tropism | Spleen; Stomach | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Zingiberales
-->Family: Zingiberaceae
-->Genus: Alpinia
-->Species: Alpinia officinarum
|
||
| Pair Name | Norizalpinin, Fluorouracil | |||
| Partner Name | Fluorouracil | |||
| Disease Info | [ICD-11: 2B70] | Esophageal cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Down-regulation | Expression | IL1B | hsa3553 | |
| Down-regulation | Expression | NLRP3 | hsa114548 | |
| In Vitro Model | Eca-109 | Esophageal squamous cell carcinoma | Homo sapiens (Human) | CVCL_6898 |
| OE19 | Esophageal adenocarcinoma | Homo sapiens (Human) | CVCL_1622 | |
| Result | Our results indicated that galangin played a synergistic anticancer role through NLRP3 inflammasome inhibition when paired with FU-5. | |||
| Pair Name | Norizalpinin, Cisplatin | |||
| Partner Name | Cisplatin | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Expression | BID | hsa637 | |
| Down-regulation | Expression | RELA | hsa5970 | |
| Down-regulation | Expression | STAT3 | hsa6774 | |
| In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
| In Vivo Model | A549/DDP cells were harvested, 5×10⁶ cells were in jected subcutaneously into the right oxter of mice | |||
| Result | Our data indicated a novel therapeutic strategy to potentiate DDP-induced anti-tumor effect in lung cancer cells with DDP resistance by GG through inactivating p-STAT3/p65 and Bcl-2 pathways. | |||
| Pair Name | Norizalpinin, Cisplatin | |||
| Partner Name | Cisplatin | |||
| Disease Info | [ICD-11: 2A60.Z] | Acute myeloid leukemia | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| In Vitro Model | HL-60 | Adult acute myeloid leukemia | Homo sapiens (Human) | CVCL_0002 |
| L1210 | Leukemia | Mus musculus (Mouse) | CVCL_0382 | |
| Result | We assume that tested flavonoids affect the important biological activities connected with cancer chemotherapy and chemoprevention as they differently modulated the sensitivity of cells to cis-Pt treatment. QU is presented as pro-apoptotic agent and GA as agent with anti-apoptotic potential. | |||
| Pair Name | Norizalpinin, Imatinib | |||
| Partner Name | Imatinib | |||
| Disease Info | [ICD-11: 2B33.4] | Leukemia | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
| Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
| Down-regulation | Expression | CDK1 | hsa983 | |
| Down-regulation | Expression | CDK4 | hsa1019 | |
| Down-regulation | Expression | RB1 | hsa5925 | |
| In Vitro Model | K-562 | Blast phase chronic myelogenous leukemia | Homo sapiens (Human) | CVCL_0004 |
| KCL-22 | Chronic myelogenous leukemia, BCR-ABL1 positive | Homo sapiens (Human) | CVCL_2091 | |
| Result | Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells | |||
| No. | Title | Href |
|---|---|---|
| 1 | Galangin Enhances Anticancer Efficacy of 5-Fluorouracil in Esophageal Cancer Cells and Xenografts Through NLR Family Pyrin Domain Containing 3 (NLRP3) Downregulation. Med Sci Monit. 2021 Dec 17;27:e931630. doi: 10.12659/MSM.931630. | Click |
| 2 | Galangin (GG) combined with cisplatin (DDP) to suppress human lung cancer by inhibition of STAT3-regulated NF-κB and Bcl-2/Bax signaling pathways. Biomed Pharmacother. 2018 Jan;97:213-224. doi: 10.1016/j.biopha.2017.10.059. | Click |
| 3 | Effects of flavonoids on cisplatin-induced apoptosis of HL-60 and L1210 leukemia cells. Leuk Res. 2003 Jan;27(1):65-72. doi: 10.1016/s0145-2126(02)00063-2. | Click |
| 4 | Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells. Cancer Lett. 2008 Jul 8;265(2):289-97. doi: 10.1016/j.canlet.2008.02.025. | Click |
